cd34 166er Search Results


cd34 166 er  (fluidigm)
93
fluidigm cd34 166 er
a Heatmap of single cell RNA-seq showing z -score mean expression of genes driving GO signatures in cell types with exemplar GO terms annotated. GO analysis performed on significant cell type markers (two-sided Wilcoxon Rank sum Test, FDR correction, p -adjust < 0.01). b tSNE projection of fibroblasts coloured by major subsets ( n = 12 DD patients) in single cell RNA-seq. c tSNE projections of CyTOF analysis for representative DD nodule showing three major fibroblasts subsets ( n = 6 DD patients). Scale bar represents normalised protein expression. d Heatmap of single cell RNA-seq showing mean z -score expression of top 10 marker genes for each fibroblast subset ( n = 12 DD patients). e tSNE projections of single cell RNA-seq showing fibroblasts coloured by ICAM1 and IL6 expression in scaled (log(UMI + 1) ( n = DD 12 patients). f Representative density plots of flow cytometry analysis showing ICAM1 + fibroblast in freshly isolated cells from matched DD nodule and cord ( n = 8 DD patients). g Dot plot of chemotaxis assay showing migration of THP-1 cells after incubation with ICAM1 −/+ sorted populations ( n = 11 DD patients). Two-sided paired t test, p value = 0.0051. h Box and whisker plots of flow cytometry analysis showing the percentage of cells (proportion) for fibroblast subsets <t>(CD34</t> + , ICAM1 + and PDPN + ) in Dupuytren’s nodules and cords as a proportion of total fibroblasts. Two-sided unpaired t test, mean ± SEM ( n = 8 DD patients). ICAM1 range 3–32%, median 8% and box bounds 5–17%. <t>CD34</t> range 13–50%, median 25% and box bounds 22–30%. PDPN range 42–63%, median 48% and box bounds 45–55%. Box bounds are first and third quantiles.
Cd34 166 Er, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd34+166er/pmc07265502-238-5-9?v=fluidigm
Average 93 stars, based on 1 article reviews
cd34 166 er - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


a Heatmap of single cell RNA-seq showing z -score mean expression of genes driving GO signatures in cell types with exemplar GO terms annotated. GO analysis performed on significant cell type markers (two-sided Wilcoxon Rank sum Test, FDR correction, p -adjust < 0.01). b tSNE projection of fibroblasts coloured by major subsets ( n = 12 DD patients) in single cell RNA-seq. c tSNE projections of CyTOF analysis for representative DD nodule showing three major fibroblasts subsets ( n = 6 DD patients). Scale bar represents normalised protein expression. d Heatmap of single cell RNA-seq showing mean z -score expression of top 10 marker genes for each fibroblast subset ( n = 12 DD patients). e tSNE projections of single cell RNA-seq showing fibroblasts coloured by ICAM1 and IL6 expression in scaled (log(UMI + 1) ( n = DD 12 patients). f Representative density plots of flow cytometry analysis showing ICAM1 + fibroblast in freshly isolated cells from matched DD nodule and cord ( n = 8 DD patients). g Dot plot of chemotaxis assay showing migration of THP-1 cells after incubation with ICAM1 −/+ sorted populations ( n = 11 DD patients). Two-sided paired t test, p value = 0.0051. h Box and whisker plots of flow cytometry analysis showing the percentage of cells (proportion) for fibroblast subsets (CD34 + , ICAM1 + and PDPN + ) in Dupuytren’s nodules and cords as a proportion of total fibroblasts. Two-sided unpaired t test, mean ± SEM ( n = 8 DD patients). ICAM1 range 3–32%, median 8% and box bounds 5–17%. CD34 range 13–50%, median 25% and box bounds 22–30%. PDPN range 42–63%, median 48% and box bounds 45–55%. Box bounds are first and third quantiles.

Journal: Nature Communications

Article Title: Cellular census of human fibrosis defines functionally distinct stromal cell types and states

doi: 10.1038/s41467-020-16264-y

Figure Lengend Snippet: a Heatmap of single cell RNA-seq showing z -score mean expression of genes driving GO signatures in cell types with exemplar GO terms annotated. GO analysis performed on significant cell type markers (two-sided Wilcoxon Rank sum Test, FDR correction, p -adjust < 0.01). b tSNE projection of fibroblasts coloured by major subsets ( n = 12 DD patients) in single cell RNA-seq. c tSNE projections of CyTOF analysis for representative DD nodule showing three major fibroblasts subsets ( n = 6 DD patients). Scale bar represents normalised protein expression. d Heatmap of single cell RNA-seq showing mean z -score expression of top 10 marker genes for each fibroblast subset ( n = 12 DD patients). e tSNE projections of single cell RNA-seq showing fibroblasts coloured by ICAM1 and IL6 expression in scaled (log(UMI + 1) ( n = DD 12 patients). f Representative density plots of flow cytometry analysis showing ICAM1 + fibroblast in freshly isolated cells from matched DD nodule and cord ( n = 8 DD patients). g Dot plot of chemotaxis assay showing migration of THP-1 cells after incubation with ICAM1 −/+ sorted populations ( n = 11 DD patients). Two-sided paired t test, p value = 0.0051. h Box and whisker plots of flow cytometry analysis showing the percentage of cells (proportion) for fibroblast subsets (CD34 + , ICAM1 + and PDPN + ) in Dupuytren’s nodules and cords as a proportion of total fibroblasts. Two-sided unpaired t test, mean ± SEM ( n = 8 DD patients). ICAM1 range 3–32%, median 8% and box bounds 5–17%. CD34 range 13–50%, median 25% and box bounds 22–30%. PDPN range 42–63%, median 48% and box bounds 45–55%. Box bounds are first and third quantiles.

Article Snippet: CD252 169-Tm (3166007B, ML5, Fluidigm), CD34 166-Er (Catalog:3166012B, Clone:581, Fluidigm), CD45 141-Pr (Catalog: 3141009B, Clone: HI30, Fluidigm), HLAD A, B C 142-Nd (Catalog: 3142007B, Clone: HCD57, Fluidigm), CD19 143-Nd (Catalog: 3144007 A, Clone:NP6G4, Fluidigm), HLA-DR 89-Y (Catalog: 3173005B, L243, Fluidigm), CD3 189-Y (Catalog: 3158021 A, Clone: 24E10, Fluidigm), B-catenin 176-Lu (Catalog: 3147005 A, Clone:D10A8, Fluidigm), CD55 174-Yb (Catalogue; 3148015B, Clone: JS11, Fluidigm), CD146 155-Nd (3155006B, P1H12, Fluidigm), CD29 156-Gd (3156007B, TS2/16, Fluidigm), CD82 158Gd (3158025B, ASL-24, Fluidigm), CD90 172-Yb (3173011B, 5E10, Fluidigm), TGFb 150-Nd (3163010B, CloneTW46H10, Fluidigm) CD163 145-Nd (3145010B, GHI/61, Fluidigm), Ki-67 168-Er (3168007B, B56, Fluidigm), CD54 170-Er (3170014B, HA58, Fluidigm), CD68 171-Yb (3171011B, Y1/82A, Fluidigm), CD9 172-Yb (Cat. No. 312102, Biolegend), CD252 150-Nd (326302, Biolegend), PGLA2 172-Yb (MAB5374, R&D Systems), a-SMA 156-Gr (MAB1420, 1A4, R&D Systems), gp38 155-Gd (AF3670-SP, R&D Systems), PDGFRB 154-Sm (SAB4700458, 18A2, Sigma Aldrich), MMP14 149-Sm (MAB9181-SP, 128527 R&D Systems), Cad-11 148-Nd (AF1790-SP, R&D Systems) and FAP 147-Sm (MAB3715-SP, 427819 RD Systems).

Techniques: RNA Sequencing, Expressing, Marker, Flow Cytometry, Isolation, Chemotaxis Assay, Migration, Incubation, Whisker Assay